اكتشاف الدواء
منشورA generative-AI-designed molecule in a phase 2a IPF trial
Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.
Pharma.AI · Insilico Medicine · rentosertib (ISM001-055)
ورقة · 2025اقرأ الحالة